Resistant tuberculosis: A molecular review;Tuberculose resistente: Revisão molecular

Revista de Saude Publica

Volumn 36, Issue 4, 2002, Pages 525-532

  Rossetti, Maria Lúcia Rosa ^a   de Moura Valim, Andréia Rosane ^a   Silva, Márcia Susana Nunes ^a   Rodriguez, Vívian Sumnienski ^a  

^a Fundacao Estadual de Producao   (Brazil)

Author keywords

Antitubercular agents, pharmacokinetics; Drug resistance, multiple, isoniazid, pharmacokinetics; Ethambutal, pharmacokinetics; Mycobacterium tuberculosis, drug effects; Pyrazinamide, pharmacokinetics; Rifampin, pharmacokinetics; Streptomycin, pharmacokinetics; Tuberculosis, drug therapy; Tuberculosis, multidrug resistant; Tuberculosis, prevention control

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ARTICLE; BACTERIAL GENE; BACTERIAL GENETICS; BACTERIUM DETECTION; BACTERIUM ISOLATE; CHROMOSOME MUTATION; COMMUNITY CARE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG SENSITIVITY; HUMAN; MULTIDRUG RESISTANCE; MUTANT; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REGULATORY MECHANISM; STRAIN DIFFERENCE; TUBERCULOSIS; TUBERCULOSIS CONTROL;

EID: 0036702512     PISSN: 00348910     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0034-89102002000400021     Document Type: Article

References (45)

1. Altamirano M, Marostenmaki J, Wong A, Fitzgerald M, Black WA, Smith JA. Mutations in the catalase-peroxidase gene from isoniazid-resistant Mycobacterium tuberculosis isolates. J Infect Dis 1994;169:1162-5.
2. Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS, Wilson T, et al. InhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994;263:227-30.
3. Blanchard JS. Molecular mechanisms of drug resistance in Mycobacterium tuberculosis. Annu Rev Biochem 1996;65:215-39.
4. Brennan PJ, Nakaido H. The envelope of mycobacteria. Annu Rev Biochem 1995;64:29-63.
5. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998;393:537-44.
6. Cooksey RC, Morlock GP, McQueen A, Glickman SE, Crawford JT. Characterization of streptomicyn resistance mechanism among Mycobacterium tuberculosis isolates from New York City. Antimicrob Agents Chemother 1996;40:1186-8.
7. Cutler RR, Wilson P, Villarroel J, Clarke, FV. Evaluating current methods for determination of the suceptibility of mycobacteria to pyrazinamide, conventional, radiometric Bactec and two methods of pyrazinamidase testing. Lett Appl Microbiol 1997;24:127-32.
8. David HL. Basis for lack of drug suceptibility of atypical mycobacteria. J Infect Dis 1981;3:878-84.
9. Dobner P, Rush-Gerdes S, Bretzel G, Feldmann K, Rifai M, Loscher P et al. Usefullness of Mycobacterium tuberculosis genomic mutations in the genes katG and inhA for the prediction of isoniazid resistance. Int J Tuberc Lung Dis 1997;1:365-9.
10. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. JAMA 1999;282:677-86.
11. Finken M, Kirshner F, Meier A, Wrede A, Bottger E. Molecular basis of streptomycin resistance in Mycobacterium tuberculosis: Alterations of the ribosomal protein S12 gene and point mutations within a funcional 16S ribosomal RNA pseudoknot. Mol Microbiol 1993;9:1239-46.
12. Garvin RT, Biswas DW, Gorini L. The effects of streptomycin or dihydrostreptomicin binding to 16S rRNA or to 30S ribossomal subunits. Proc Natl Acad Sci USA 1974;71:3814-8.
13. Gingeras TR, Ghandour G, Wang E, Berno A, Small PM, Drobniewski F. Simultaneous genotyping and species identification using hybridization pattern recognition analysis of generic Mycobacterium DNA arrays. Genome Res 1998;8:435-48.
14. Hewlett D, Horn DL, Alfalfa C. Drug resistant tuberculosis: inconsistent results of pyrazinamide suceptibility testing. JAMA 1995;273:916-7.
15. Honoré N, Cole ST. Streptomycin resistance in mycobacteria. Antimicrob Agents Chemoter 1994;11:773-9.
16. Jin DJ, Gross CA. Mapping and sequencing of mutations in the Escherichia coli rpoB gene that lead to rifampicin resistance. J Mol Biol 1988;202:45-58.
17. Kapur V, Li LL, Londanescu S, Hamrick MR, Wanger A, Kreiswirth BN et al. Characterization by automated DNA sequencing of mutations in the gene rpoB encoding the RNA polymerase β subunit in rifampin-resistant Mycobacterium tuberculosis strains from New York City and Texas. J Clin Microbiol 1994;32:1095-8.
18. Kelley CL, Rouse DA, Morris SL. Analisys of ahpC gene mutations in isoniazid-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1997;41:2057-8.
19. Khoo KH, Douglas E, Azadi P, Inamine JM, Besra GS, Mikusova K, et al. Truncated structural variants of lipoarabinomannan in ethambutol drug-resistant strains of Mycobacterium smigmatis. Inhibition of arabinan biosynthesis by ethambutol. J Biol Chen 1996;271:28682-90.
20. Konno K, Nagayama H, Oka S. Nicotinamidase in mycobacteria: um method for distinguishing bovine type tubercle bacilli from other mycobacteria. Nature 1959;184:1743-4.
21. Mdluli K, Slayden RA, YaQi Z, Ramaswamy S, Pan X, Mead D, et al. Inhibition of a Mycobacterium tuberculosis β-Ketoacil ACP Synthase by Isoniazid. Sci Mag 1998;280:1607-10.
22. Mestdagh M, Fonteyne PA, Realini L, Rossau R, Jannes G, Mijs W, et al. Relationship between pyrazinamide resistance, loss of pyrazinamidase activity and mutations in the pncA locus in multidrug-resistant isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1999;43:2317-9.
23. Middlebrook G. Sterilization of tubercle bacilli by isonicotinic acid hydrazid and the incidence of variants resistant to the drug in vitro. Am Rev Tuberc 1952;65:765-7.
24. Ministério da Saúde. Centro Nacional de Epidemiologia. Coordenação de Pneumologia Sanitária. Manual de normas para o controle da tuberculose. 4 ed. Brasília (DF): Fundação Nacional da Saúde; 1995.
25. Ministério da Saúde. Fundação Nacional de Saúde. Bol Epidemiol 1999;7:1.
26. Morlock GP, Crawford JT, Butler WR, Brim SE, Sikes D, Mazurek GH, et al. Phenotypic characterization of pncA mutants of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2000;44:2291-5.
27. Musser JM. Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin Microbiol Rev 1995;8:496-514.
28. Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis 1998;79:3-29.
29. Rinder H, Thonschke A, Rusch-Gerdes S, Bretzel G, Feldmann K, Rifai M et al. Significance of ahpC promoter mutations for the prediction of isoniazid resistance in Mycobacterium tuberculosis. Eur J Clin Microbiol Infect Dis 1998;17:508-11.
30. Scorpio A, Collins DM, Whipple D, Cave D, Bates J, Zhang Y. Rapid differentiation of bovine and human tubercle bacilli based on a characteristic mutation in the bovine pyrazinamidase gene. J Clin Microbiol 1997;32:106-10.
31. Snider DE-Jr, Roper WE. The new tuberculosis. N Engl J Mud 1992;326:703-5.
32. Soini H. Musser JM. Molecular diagnosis of mycobacteria. Clin Chem 2001;47:809-14.
33. Sreevatsan S, Pan X, Stockbauer k, Williams D, Kreiswirth B, Musser JM. Characterization of rpsL and rrs mutations in streptomicin-resistant Mycobacterium tuberculosis isolates from diverse geographical localities. Antimiciob Agents Chemother 1996;40:1024-6.
34. Sreevatsan S, Pan X, Zhang Y, Kreiswirth BN, Musser JM. Mutations associated with pyrazinamidase resitance in pncA of Mycobacterium tuberculosis complex organisms. Antimicrob Agents Chemother 1997;41:636-40.
35. Telenti A, Iseman M. Drug resistant tuberculosis. What do we do now? Drugs 2000;59:171-9.
36. Telenti A, Imboden F, Marchesi F, Schmidheini T, Bodmer T. Direct, automated detection of rifampin-resistant Mycobacterium tuberculosis by polymerase chain reaction and single-strand conformation polymorphism analysis. Antimicrob Agents Chemother 1993;37:2054-8.
37. Troesch A, Nguyen H, Miyada S, Gingeras TR, Kaplan PM, Cros P, et al. Mycobacterium species identification and rifampin resistance testing with high-density DNA probe arrays. J Clin Microbiol 1999;37:49-55.
38. Valim ARM, Rossetti MLR, Ribeiro MO, Zaha A. Mutations in the, rpoB gene of multidrug-resistant Mycobacterium tuberculosis isolates from Brasil. J Clin Microbiol 2000;38:3119-22.
39. Vareldzis BF, Grosset J, de Kantor I, Crofton J, Laszlo A, Felten M et al. Drug-resistant tuberculosis: laboratory issues. World Health Organization Recomendations. Tuber Lung Dis 1994;75:1-7.
40. Wengenack NL, Todorovic S, Yu L, Rusnak F. Evidence for differential binding of isoniazid by Mycobacterium tuberculosis katG and the isoniazid-resistant mutant katG (S315T). Biochemistry 1998;37:15825-34.
41. Willians DL, Waguespack C, Eisenach K, Crawford JT, Portaels F, Salfinger M, et al. Characterization of rifampin resistance in pathogenic mycobacteria. Antimicrob Agents Chemother 1994;38:2380-6.
42. Wilson TM, Collins DM. ahpC, a gene involved in isoniazid resistance of the Mycobacteruim tuberculosis complex. Mol Microbiol 1996;19:1025-34.
43. World Health Organization. Global tuberculosis control: WHO report. Geneva; 1999.
44. Zhang Y, Telenti A. Genetics of drug resistance in Mycobacterium tuberculosis. In: Hatfull GF, Jacobs WR-Jr. Molecular of mycobacteria. Washington (DC): ASM Press; 2000. p. 235-54.
45. Zhang Y, Heym B, Allen B, Young D, Cole S. The catalase peroxidase gene and isoniazid resistance of M. tuberculosis. Nature 1992;385:591-3.